Skip to content
ANAVEX
ANAVEXANAVEX
  • HOME
  • ABOUT US
  • OUR TEAM
  • NEWS
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
    • Presentations
  • JOIN US
Search
  • HOME
  • ABOUT US
  • OUR TEAM
  • NEWS
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
    • Presentations
  • JOIN US
View allAlzheimer's DiseaseAnavex2-73EventsNews ReleasesPIPELINEPressUncategorized

AAT Presentation

Assessment of ANAVEX 2-73 in a MECP2 Rett Syndrome Mouse Model.

Sigma-1 Receptor Agonists Inhibit Oligodendrocyte Cytotoxicity Induced by Molecules Involved in Cell Damage in Multiple Sclerosis.

New Alzheimer’s Drug ANAVEX 2-73: A Phase 2a Study, Clinical Safety, Tolerability and Maximum Tolerated Dose finding in mild-to-moderate Alzheimer’s Patients.

Novel Anti-Seizure Compound ANAVEX 2-73 a Sigma-1 Receptor Agonist in Multiple Seizure Models.

New Exploratory Alzheimer’s Drug ANAVEX 2-73: Assessment of Safety and Cognitive Performance in a Phase 2a Study in mild-to-moderate Alzheimer’s Patients.

New Exploratory Alzheimer’s Drug ANAVEX 2-73 Changes in Electrophysiological Markers in Alzheimer’s Disease – First Patient Data from an ongoing Phase 2a Study in mild-to-moderate Alzheimer’s Patients.

Mitochondrial protection by the mixed muscarinic/sigma-1 ligand ANAVEX2-73, a tetrahydrofuran derivative, in Ab25–35 peptide-injected mice, a nontransgenic Alzheimer’s disease model.

A Phase 1 Dose Escalation Study to Investigate Safety, Tolerability, and Pharmacokinetics of ANAVEX 2-73 in Healthy Male Subjects.

The Anticipated Clinical Effect of the new Alzheimer drug ANAVEX 2-73 in a Calibrated Quantitative Systems Pharmacology Platform.

12345
ANAVEX

ANAVEX® is a trademark of Anavex®Life Sciences Corp. - 2019 All Rights Reserved

Go to Top